Psychometric Evaluation of the PROMIS SD-SF-8b Instrument in Individuals Experiencing Vasomotor Symptoms Due to Menopause
Source : https://pubmed.ncbi.nlm.nih.gov/37990323/
ClinicalTrials.gov numbers: NCT04003155 and NCT04003142.
The psychometric properties of the PROMIS SD-SF-8b support its use to measure sleep disturbance in women with vasomotor symptoms due to menopause.
Share
Menopause has minimal effect on the physiological responses to hypoxia in physically fit women and does not increase the risk of acute mountain sickness. Postmenopausal women have an increased risk of urinary tract infections, which may be exacerbated during mountain travel.
Share
Use of MHT in Women With Cardiovascular Disease: a Systematic Review and Meta-Analysis
Source : https://pubmed.ncbi.nlm.nih.gov/37933495/
This systematic review assesses the effect of menopausal hormone therapy (MHT) on cardiovascular outcomes and risk factors in postmenopausal women with cardiovascular disease (CVD).
No significant differences were observed between MHT users and controls regarding primary outcomes of nonfatal MI, CV death, or stroke. No differences in frequency of angina, HF, and TIAs were observed.
Share
Systematic Review and Meta-Analysis of the Effects of Menopause Hormone Therapy on Risk of Alzheimer’s Disease and Dementia
Source : https://www.frontiersin.org/articles/10.3389/fnagi.2023.1260427/full
Despite a large preclinical literature demonstrating neuroprotective effects of estrogen, use of menopausal hormone therapy (HT) for Alzheimer's disease (AD) risk reduction has been controversial.
In midlife, ET use was associated with a 32% reduction in dementia risk, while EPT use showed a non-significant 23% risk reduction as compared to non-use.
Share
Cardiovascular Risk Assessment in Women: Which Women Are Suited for Menopausal Hormone Therapy?
Source : https://pubmed.ncbi.nlm.nih.gov/37931647/
Individual risk assessment for atherosclerotic cardiovascular disease is important for safe menopausal hormone prescription.
Estimation of ASCVD risk in perimenopausal women needing MHT can be tailored by adding female-specific risk factors and a CAC score with computed tomography if there is doubt about individual risk.
Share